Deutsche Bank AG Grows Stock Holdings in Qiagen N.V. $QGEN

Deutsche Bank AG increased its stake in shares of Qiagen N.V. (NYSE:QGEN) by 9.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,907,801 shares of the company’s stock after purchasing an additional 697,342 shares during the period. Deutsche Bank AG owned approximately 3.74% of Qiagen worth $355,614,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Danske Bank A S purchased a new position in shares of Qiagen during the third quarter valued at approximately $36,000. Smartleaf Asset Management LLC raised its holdings in shares of Qiagen by 1,383.3% during the third quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock valued at $39,000 after purchasing an additional 830 shares during the last quarter. Manchester Capital Management LLC purchased a new position in shares of Qiagen during the fourth quarter valued at approximately $42,000. Global Retirement Partners LLC raised its holdings in shares of Qiagen by 279.9% during the fourth quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock valued at $52,000 after purchasing an additional 851 shares during the last quarter. Finally, Allworth Financial LP raised its holdings in shares of Qiagen by 23.2% during the third quarter. Allworth Financial LP now owns 1,358 shares of the company’s stock valued at $61,000 after purchasing an additional 256 shares during the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Price Performance

Shares of NYSE:QGEN opened at $37.03 on Thursday. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.21 and a quick ratio of 2.57. Qiagen N.V. has a 1-year low of $32.53 and a 1-year high of $57.81. The company has a market capitalization of $7.63 billion, a P/E ratio of 19.34, a P/E/G ratio of 3.76 and a beta of 0.66. The firm’s 50 day simple moving average is $37.19 and its two-hundred day simple moving average is $44.17.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.54 earnings per share for the quarter, meeting the consensus estimate of $0.54. Qiagen had a net margin of 19.16% and a return on equity of 14.40%. The business had revenue of $492.32 million for the quarter, compared to the consensus estimate of $496.15 million. During the same quarter in the previous year, the firm earned $0.56 earnings per share. Research analysts expect that Qiagen N.V. will post 2.43 EPS for the current fiscal year.

Qiagen Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Tuesday, July 14th. Investors of record on Tuesday, July 7th will be given a dividend of $0.35 per share. This is an increase from Qiagen’s previous annual dividend of $0.26. This represents a dividend yield of 104.0%. The ex-dividend date is Tuesday, July 7th. Qiagen’s dividend payout ratio (DPR) is 13.61%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on QGEN. JPMorgan Chase & Co. lowered their target price on Qiagen from $60.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday, April 29th. Wall Street Zen cut Qiagen from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Robert W. Baird set a $43.00 target price on Qiagen and gave the stock an “outperform” rating in a research report on Wednesday, April 29th. Barclays set a $38.00 target price on Qiagen and gave the stock an “equal weight” rating in a research report on Wednesday, April 29th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $43.00 target price on shares of Qiagen in a research report on Thursday, April 30th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Qiagen presently has an average rating of “Hold” and a consensus target price of $44.98.

Qiagen Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.